Bolar
Executive Summary
Generic firm agrees to pay $7 mil. to Warner-Lambert to settle lawsuit concerning damages to the brandname drugs caused by fraudulently approved ANDAs for Dilantin, Meclomen and Procain ("The Pink Sheet" Oct. 21, T&G-13), Bolar announced Feb. 3. Warner-Lambert filed suit in Newark, N.J. federal court last autumn against Bolar and the company's former President Robert Shulman. Bolar has agreed to pay $1 mil. to Warner-Lambert upon the signing of the settlement, $2 mil. on or before March 1, 1992 and $1 mil. every 15 months until Jan. 1, 1997.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth